[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616414":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Naples","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mirabegron arm",null,"Mirabegron will be administered per os at the dose of 50 mg\u002Fday for 12 months",[13],"Drug: Mirabegron 50mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Control arm","Solifenacin will be administered per os at the dose of 5mg\u002Fday for 12 months",[18],"Drug: Solifenacin 5mg",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Mirabegron 50mg","Mirabegron (50mg\u002Fday per os) will be administered in patients with dry AMD and overactive bladder (MMirabegron arm)",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Solifenacin 5mg","Solifenacin (5mg\u002Fday per os) will be administered in control group (dry amd and overactive bladder)",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Mario D Toro, Professor","CONTACT","+393495158220","mariodamiano.toro@unina.it",[36],{"facility":37,"status":10,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"Federico II","Naples","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],14.26811,40.85216,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mario Damiano Toro","Principal Investigator, MD, PhD",[52],{"name":53,"class":6},"Medical University of Lublin","100616414","mirabegron-in-patients-with-age-related-macular-degeneration-100616414",false,"NCT07305298","Mirabegron in Patients With Age-Related Macular Degeneration","Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial","Inclusion Criteria:\n\n* Age subjects 50 and 80 years-old\n* Ability to express informed consent\n* Early or moderate dry AMD according to ARDS classification\n* Overreactive bladder\n* Visual acuity greater than BCVA 65 EDTRS letters.\n\nExclusion Criteria:\n\n* • Any medical condition which contraindicates the use of beta-agonists\n\n  * Uncontrolled hypertension\n  * Tachycardia or atrial fibrillation\n  * Any allergies to the beta-agonists\n  * Renal or hepatic failure\n  * Long QT or concomitant treatment with drugs that cause lengthening of the QT interval\n  * Any sign of ocular inflammation\n  * xudative AMD\n  * Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)\n  * Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.\n  * Pregnancy\n  * Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. malignancy, uncontrolled or cardiovascular diseases)","ALL","50 Years","80 Years",{"count":65,"type":66},312,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.\n\nThe main question it aims to answer is:\n\n• Is there any change in outer retina morphology in patients treated?\n\nResearchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.\n\nParticipants will:\n\n* Take Mirabegron or Solifenacin every day for 12 months\n* Visit the clinic once every 6 months for checkups and tests",[70,71],"Dry AMD","Overactive Bladder","NOT_YET_RECRUITING","2026-02-04",{"date":75,"type":76},"2026-02-06","ACTUAL",{"date":78,"type":66},"2026-04-01",{"date":80,"type":66},"2026-12-01",{"name":5,"class":6},1]